Lv5
1140 积分 2023-11-20 加入
Identification of a Novel Osimertinib-Sensitive Mutation, EGFR H773L, in a Chinese Patient With NSCLC
1个月前
已完结
Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non–Small-Cell Lung Cancer
1个月前
已完结
Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis
1个月前
已完结
Selecting systemic treatment for metastatic neuroendocrine tumors of the lung—current evidence and clinical implications
4个月前
已完结
Anaplastic Lymphoma Kinase (ALK) Positive Neuroendocrine Tumor of Lung With Favorable Response to Alectinib (ALK Inhibitor)
4个月前
已完结
Twelve cases of pituitary metastasis: a case series and review of the literature
5个月前
已完结
ALK-EML4 Fusion in Small Cell Lung Cancer: Clinical and Molecular Insights From a Rare Case
5个月前
已完结
The safety and efficacy for the treatment of alectinib in a women with ALK-positive lung cancer delivered a healthy male neonate throughout Pregnancy: A case report
5个月前
已完结
EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: A case report and review of the literature
5个月前
已完结
皖公网安备34019202002308
